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Simple Summary: There is a need to demonstrate additional clinical value/utility for PET/MRI in
oncology which moves beyond simple diagnosis. We believe that our currently submitted work rep-
resents an initial step in realizing the goal of moving PET/MRI beyond simple diagnosis. We report
how texture analysis of parametric images depicting tumor fractional water content derived from
routine PET/MRI Dixon acquisitions shows good inter-operator agreement, generates biologically
relevant information related to total lesion glycolysis and gene mutation count, and provides prog-
nostic information that can potentially unlock new clinical applications for patients with colorectal
cancer. This research study resulted from a long-standing multi-disciplinary collaboration between
the nuclear medicine physicians at our institute and experts in quantitative imaging, MRI radiology,
GI histology, clinical oncology in colorectal cancer, and several gastrointestinal surgeons at various
local hospitals.
Abstract: To assess the capability of fractional water content (FWC) texture analysis (TA) to generate
biologically relevant information from routine PET/MRI acquisitions for colorectal cancer (CRC)
patients. Thirty consecutive primary CRC patients (mean age 63.9, range 42–83 years) prospectively
underwent FDG-PET/MRI. FWC tumor parametric images generated from Dixon MR sequences
underwent TA using commercially available research software (TexRAD). Data analysis comprised
(1) identification of functional imaging correlates for texture features (TF) with low inter-observer
variability (intraclass correlation coefficient: ICC > 0.75), (2) evaluation of prognostic performance
for FWC-TF, and (3) correlation of prognostic imaging signatures with gene mutation (GM) profile.
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Of 32 FWC-TF with ICC > 0.75, 18 correlated with total lesion glycolysis (TLG, highest: rs = −0.547,
p = 0.002). Using optimized cut-off values, five MR FWC-TF identified a good prognostic group
with zero mortality (lowest: p = 0.017). For the most statistically significant prognostic marker,
favorable prognosis was significantly associated with a higher number of GM per patient (medians:
7 vs. 1.5, p = 0.009). FWC-TA derived from routine PET/MRI Dixon acquisitions shows good
inter-operator agreement, generates biological relevant information related to TLG, GM count, and
provides prognostic information that can unlock new clinical applications for CRC patients.
Keywords: colorectal cancer; magnetic resonance imaging; Dixon sequence; positron emission
tomography; texture analysis
1. Introduction
By combining two powerful imaging modalities, PET/MRI has the potential to sig-
nificantly impact the care of patients with cancer. However, current research has shown
only limited diagnostic benefit over PET/CT and supplementary clinical roles need to
be identified to support the use of PET/MRI in routine clinical practice [1]. Extending
the range of biologically relevant information generated from PET/MRI by exploiting the
quantitative imaging capabilities of the MRI component represents one approach to achiev-
ing this goal. Discovery of novel parameters with prognostic or predictive significance
could create opportunities for PET/MRI to contribute to precision medicine [1].
Attenuation correction (AC) of PET images acquired using oncological PET/MRI is
commonly performed using two-point Dixon sequences which separate fat and water tissue
components. However, the biological relevance and possible clinical value of quantitative
analysis of these sequences during oncological PET/MRI remains relatively unexplored. A
single study incorporated quantitative analysis of separate fat- and water- weighted images
derived from two-point Dixon sequences into a PET/MRI radiomic study of renal cancer
but did not use the data to generate parametric maps of absolute fractional fat or water
content within the tumor [2]. To date, PET/MRI measurements of the fractional fat (signal
fat fraction) or water content of tissues have been limited to comparative assessments of
bone marrow factional water content and glucose metabolism in healthy volunteers [3], a
cohort of oncological patients with a variety of tumor types [4], and a series of patients with
plasma cell dyscrasias [5]. The authors have been unable to identify any PET/MRI studies
reporting quantitative imaging of fractional water content in solid tumors, despite previous
pre-clinical research indicating increased water fraction within tumors as compared to
normal tissues [6,7].
Computerized image analysis offers a means to increase the range of biologically
relevant parameters available from an individual quantitative image. A commonly used
method calculates an array of measures reflecting the distribution of image intensity values
within a tumor region displayed as a histogram. Texture analysis (TA) represents an
extension of this approach, with one widely used technique employing image filtration to
highlight specified image features prior to histogram analysis [8]. This filtration-histogram
approach to TA has attracted attention to assess intra-tumoral heterogeneity [9–11]. Intra-
tumoral heterogeneity is related to tumor aggression, as reflected by numerous studies
reporting an association between tumor texture and patient outcome (survival and/or
treatment response) for a wide range of image modalities and tumor types [12–21].
The biological relevance of imaging assessments of intra-tumoral heterogeneity has
been further highlighted by radiogenomic associations between imaging heterogeneity
and gene mutation status recently reported for a number of tumor types [22]. Multi-
functional/parametric imaging signatures derived from TA have shown associations with
PBRM1 mutation status in clear cell renal cell carcinoma on CT [23], KRAS mutation status
in colorectal cancer on PET/CT [24], KRAS and EGFR mutation status in non-small cell
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lung cancer on CT [25,26], IDH mutation status (including 1p19q genotyping) in glioma on
MRI [27], and KIT exon 11 mutation in gastrointestinal stromal tumors on CT [28].
Colorectal cancer (CRC) is the third most common malignancy, with 1.7 million new
cases and 860,000 deaths worldwide in 2018 [29]. Imaging plays a key role in the staging of
patients with this disease so that the most appropriate therapeutic strategy can be selected.
Contrast-enhanced computed tomography (CT) remains the mainstay investigation for
staging CRC but there has been recent interest in the potential for PET/MRI to provide
additional value by allowing better characterization of loco-regional lymph nodes and
greater sensitivity to metastatic lesions, particularly in the liver [30,31]. However, PET/MRI
is a costly procedure and it is uncertain whether the added benefits of PET/MRI will justify
the additional costs if this modality is used for diagnosis alone. The ability to generate
multiple quantitative images from a single examination represents a major advantage for
PET/MRI over other imaging modalities. Each quantitative image provides a potential
source for biomarkers, which could feasibly increase the clinical value and cost-effectiveness
of PET/MRI in oncology [1].
The feasibility of applying TA to PET and MRI data acquired during PET/MRI has
been reported [2,32,33], but none of these studies used TA to assess the heterogeneity of
tumor fractional water content (FWC) as measured from Dixon sequences. Our study
therefore aims to assess the capability of texture analysis of FWC images to generate
additional biologically relevant information from routine PET/MRI acquisitions, with
the potential to extend clinical application beyond simple diagnosis for patients with
colorectal cancer.
2. Materials and Methods
2.1. Study Design
A prospective observational pilot study was performed. The study protocol was
approved by the local Institutional Ethics Review Board. The study design comprised
3 components, as summarized in Figure 1: (1) an evaluation of inter-observer agreement of
texture parameters, (2) identification of texture correlates for functional imaging parameters
known to be related to tumor aggression, (3) an assessment of prognostic performance by
analysis of Overall Survival (OS), and (4) association between presence of gene mutations
and imaging signatures of prognosis.
2.2. Patients
Thirty consecutive newly diagnosed primary colorectal cancer (CRC) patients were
recruited from February 2015 to May 2016 (20 males, 10 females; mean age 63.9 years; range
42–83 years). All patients gave informed consent prior to simultaneous FDG PET/MRI
examination. OS was determined from clinical follow-up (median 25.4 months, range
5.0–31.6 months).
2.3. PET/MRI Image Acquisition
2.3.1. PET
Following a 6-hour fast, patients received an intravenous injection of 250 MBq 18F-
FDG ± 10%. After an uptake period of 60 min, all imaging was performed on an integrated
PET/MR instrument (3T mMR Biograph, Siemens Healthcare, Erlangen, Germany). The
PET emission scan was obtained over the same anatomical area. All acquisitions were
carried out in 3-dimensional mode, consisting of an emission scan of 5 min/bed position.
Reconstruction of PET data was carried out using ordered subset expectation maximization
(OSEM) with 21 subsets and 3 iterations and a 5 mm full width half maximum (FWHM)
Gaussian filter (FoV 359 × 359 mm, 2 mm slice thickness, 127 slices).
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2.3.2. MRI
During this time, a 3-dimensional (3D) T1 2-point Dixon sequence was performed
with acquisition parameters as follows: axial, repetition time (TR) 4.13 ms, echo time (TE)
1–1.23 ms, TE 2–2.46 ms, FOV read 500 mm × FOV phase 390 mm, base resolution 320,
voxel size 2.1 × 1.6 × 3.0 mm, 80 slices × 3 mm thickness, and 10% slice oversampling.
Images interpolated. Breath hold time was 16 s.
A 2D DWI was also performed with acquisition parameters as follows: axial, TR
8400 ms, TE 89 ms, averages 4, FOV read 350 mm × FOC phase 274 mm, base resolution
184, voxel size 1.9 × 1.9 × 4 mm. SPAIR Fat Suppression, 32 slices × 4 mm slice thickness
with a slice gap of 0.8 mm, and 3 × b values—0, 400, 800 s/mm2. An apparent diffusion
coefficient (ADC) map was then calculated. Total scan time was 9 min 23 s.
An axial T2 half fourier single shot turbo spin echo (HASTE) was also performed to
help localize the tumor but was n t included in the analysis of this study.
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2.4. Multi-Parametric Image Analysis
Quantitative image parameters were derived from attenuation-corrected FDG-PET
data, ADC maps, and fractional water content (FWC) images (derived from water-only
and fat-only images acquired as part of the 2-point Dixon sequence).
Two independent operators constructed tumor regions of interest (ROIs) enclosing
the primary lesion from the PET/MR image displaying the largest cross-section area of
the colorectal tumor. Each operator employed a standardized procedure so that ROIs
were comparable in terms of anatomical location for all image data sets as follows. With
reference to the T2 HASTE, the axial T2 slice with the largest cross-sectional diameter of
tumor was selected. Multiple b value images were studied, and using this, an ROI was
placed on the ADC map around the tumor site using Osirix MD software (v8.0.2-Pixmeo
SARL, Geneva, Switzerland). The fat and water images corresponding to the ADC image
slice and T2 image with the largest axial diameter were selected to generate the FWC image.
The FWC image was created by dividing the individual pixel value from the water-only
image by the sum of the individual and corresponding pixel values from water-only and
fat-only images. Pixel size of the FWC image is 0.78 × 0.78 mm.
The PET emission study and MR were viewed independently and as co-registered
studies using a commercial workstation (Horos v3.3.6—Horos is a free and open source
code software-FOSS program that is distributed free of charge under the Lesser General
Public License-LGPL at horosproject.org and sponsored by Nimble Co LLC d/b/a Purview
in Annapolis, MD, USA, Figure 2). The tumor ROI on the PET image (comparable to the
above MR analysis in slice location and ROI size) was obtained for each patient using an
automated threshold method (42% of the maximum value was used as a default setting).
FDG uptake within the tumor was expressed as SUVmax, SUVmean and TLG. Tumor
ADCmean values were determined from ADC maps, as well as kurtosis and skewness values
from ADC histograms. FWC images generated from the Dixon sequences underwent tex-
ture analysis using a commercially available proprietary software called TexRAD (Feedback
Medical Ltd., Cambridge, UK, https://fbkmed.com/texrad-landing-2/, accessed on 23
April 2021). This software derives 36 texture parameters by applying a filtration-histogram
technique in which the filtration step using a Laplacian of Gaussian filter to highlight
image features of a specified size as determined by Spatial Scale Factor (SSF). A total of
5 SSF values were used (2, 3, 4, 5, and 6 mm, where SSF = 2 corresponded to fine texture
scale, SSF = 3–5 corresponded to medium texture scale, and SSF = 6 corresponded to coarse
texture scale). For each filter value, and for unfiltered data (SSF = 0), the following statistical
and histogram-based parameters were derived: mean intensity, standard deviation (SD),
entropy, mean of positive pixels (MPP), skewness, and kurtosis. Figure 2 provides an
illustration of a FWC image and the filtration process. A detailed description of the above
image filtration and quantification is described [34] and a computer modelling study has
characterized the meaning of filtration-histogram-based texture features in terms of image
features and how they relate to different components (object size, density, number) of
heterogeneity [8].
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Figure 2. PET/MRI images of a colorectal cancer patient with a descending colonic tumor: (a) FDG-PET (tumor appears
to be intensely avid); (b) ADC map (tumor appears to be highly cellular); (c) fractional water image (tumor appears to
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representing pockets of high water distribution within the tumor).
2.5. Molecular Biology
Formalin fixed paraffin embedded tissue blocks (FFPE) were cut at a thickness of
10 µm followed by DNA extraction using the Qiagen QIAamp DNA FFPE tissue kit,
according to manufacturer protocols [35]. Sequencing libraries were generated by loading
10 ng of genetic material into the Fluidigm Access Array IFC Chip with custom designed
targeted primers for KRAS (exon 2, 3, and 4), NRAS (exon 2, 3, and 4), HRAS (exon 2 and 3),
BRAF (exon 11, 12, and 15), PIK3CA (exon 2, 5, 8, 10, 14, 19, and 21), PTEN (exon 2, 4, 6, 7, 8,
and 9) and APC (exon 15 and 16). Samples were barcoded and assessed using Agilent high
sensitivity d1000 screen tape [36]. Samples were diluted to 100 pM and next-generation
sequencing was undertaken using the Ion Torrent Personal Genome Machine, according to
manufacturer protocols [37,38]. Data generated were analyzed on the Integrative Genomics
Viewer (Broads Institute). Samples were compared to the human HG19 reference genome
with a mutation frequency of 5% or above.
. . tatistic l l i
ti l analyses were performed using SP S 25.0 (IBM Corp, released 2017, IBM
SPSS Statistics for Mac, Armonk, NY, USA).
2.6.1. Inter-Operator Agreement of Texture Parameters
The inter-operator agreement of FWC texture parameters was assessed by determin-
ing intra-class correlation coefficients (ICC) for each parameter. Paired values from the
two operators were averaged for all parameters showing good (ICC > 0.75) or excellent
agreement (ICC > 0.9) [39] and included in subsequent analyses.
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2.6.2. Functional Imaging Correlates for FWC Texture Parameters
Correlations were sought between each FWC parameter and the quantitative values
derived from FDG images (SUVmax, SUVmean, TLG) and ADC maps (ADCmean, kurtosis,
and skewness from ADC histograms). These functional imaging parameters are considered
to relate to tumor aggression in CRC or other tumors. The strength of each correlation was
determined using the Spearman rank correlation coefficient (rs). The false discovery rate
was limited to 0.1 using the Benjamini–Hochberg (BH) correction procedure.
2.6.3. Prognostic Performance of FWC Texture Parameters
FWC texture parameters significantly associated with OS were identified using Kaplan-
Meier (KM) survival analysis and compared to the prognostic performance of quantitative
values determined from the FDG images and ADC maps. The analyses were performed us-
ing optimal threshold values for separating good and poor prognostic groups. Differences
between survival curves were evaluated using a non-parametric log rank test. A multivari-
ate Cox regression analysis comprising of the best significant univariate markers along with
their interactions was used to determine which parameters were independent predictors of
survival (along with the hazard ratio (HR) and the 95% confidence interval (CI)).
2.6.4. Gene Mutation Association with FWC Texture Parameters
For the FWC texture, FDG uptake and ADC metrics showing the most statistically
significant associations with survival as identified above, a non-parametric Mann–Whitney
test assessed the difference in the total number of gene mutations per patient in the good
prognostic group from the poor prognostic group as identified by that imaging marker.
In addition, a 2 × 2 contingency table assessed the presence or absence of specific gene
mutations in the good and poor prognostic group as identified by the imaging marker and
its significance was evaluated by Fisher’s exact test (2-tailed)
A p-value of less than 0.05 indicated a significant difference.
3. Results
Number of patients with clinical stages I, II, III, and IV were 2, 7, 9, and 12, respectively.
Mean tumor fractional water content (FWC) was 0.88 (range: 0.16–0.98). Mean tumor ROI
size was 1768 (range: 445–6233) pixels. The mean and range for all the FW imaging
parameters used in the study are given in the Supplementary Materials (Table S1).
3.1. Inter-Operator Agreement of FWC Texture Parameters
ICC values for FWC texture values ranged between −0.15 and 0.98 (see Table S2 for
details). Inter-observer agreement was good (ICC > 0.75) for 18 parameters (50%) and
excellent (ICC > 0.9) for 14 (39%). Four FWC texture parameters demonstrating poor or
moderate agreement (ICC < 0.75) were excluded from subsequent analyses: SD, kurtosis,
skewness at SSF = 0, and skewness at SSF = 2.
3.2. Functional Imaging Correlates for FWC Texture Parameters
Eighteen texture parameters were found to be significant correlates for TLG (Table S3).
The strongest correlation was for MPP at coarse texture scale, SSF = 6 mm (rs = −0.547,
p = 0.002, Figure 3). Four of five parameters with the strongest correlations (i.e., rs values
above 0.5 or below −0.5) were for medium or coarse texture features (SSF 5 or 6 mm). No
unfiltered texture parameters (including the FWC measure) were shown to be significant
correlates for TLG. No significant FWC texture (including the FWC measure) correlates
were identified for SUVmax or SUVmean, nor for any ADC parameter.
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Figure 3. Scatter plot showing the correlation between fractional water texture expressed as MPP at coarse texture scale,
SSF = 6 mm and TLG (rs = −0.547, p = 0.002).
3.3. Prognostic Performance of FWC Texture Parameters
Seven patients (23%) died during the follow-up period (median 25 months, range
5–32 months). Mean survival was 27 (95% confidence interval: 24–30) months.
The parameters significantly associated with survival included five derived using
texture analysis of FWC images (Table 1).
Table 1. FWC texture and functional imaging paramete s significantly associated with overall survival.
Parameter Threshold (Direction Indicates Poor Prognosis) Patients above/below Threshold p-Value
Texture
Entropy SSF = 2 ≥6.19 19/11 0.033
Entropy SSF = 3 ≥6.44 18/12 0.024
Entropy SSF = 4 ≥6.52 18/12 0.024
Entropy SSF = 5 ≥6.53 18/12 0.024
Entropy SSF = 6 ≥6.58 17/13 0.017
FDG uptake
SUVmean ≥10.1 9/21 0.047
TLG ≥378 3/27 0.016
ADC maps
Skewness ≥0.61 3/27 0.023
FWC texture expressed as entropy was significantly associated with OS for all SSF
values between 2 and 6 mm, being most significant for coarse texture scale, SSF = 6 mm
(p = 0.017). In each case, there were no deaths in the good prognosis group. Two FDG
uptake parameters (TLG and SUVmean) were significantly associated with survival, with
TLG achieving greater statistical significance (p = 0.016 vs. 0.047). The skewness of the ADC
maps was also significantly associated with survival (p = 0.023). In terms of clinical stage,
as expected, patients with higher clinical stage (≥III) had a worse outcome compared to
patients with lower clinical stage (<III), but not reaching statistical significance (p = 0.061).
Good prognostic group as defined by lower clinical stage (<III) demonstrated zero mortality.
Figure 4 compares the survival curves for FWC texture parameter entropy at coarse texture
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scale, SSF = 6 mm and FDG-PET uptak e quantified as TLG. Entropy at SSF = 6 was among
the FWC texture correlates for TLG and the statistical significances of the two survival
curves are similar. However, the value of TLG as a prognostic marker is constrained
by the small proportion of patients falling within the poor prognostic group (3 of 30).
For entropy SSF = 6, the sizes of the poor and good prognostic groups are more similar
(17 and 13, respectively). Furthermore, the good prognostic group defined using entropy
demonstrated zero mortality.
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Figure 4. Kaplan-Meier survival curves for (a) FDG-PET uptake expressed as TLG and (b) FWC
texture expressed as entropy at coarse texture scale, SSF = 6 mm.
A multivariate Cox regression analysis comprising of the best FWC texture (entropy at
SSF = 6), FDG uptake (TLG), and ADC (skewness of ADC maps) parameters demonstrated
an interaction between FWC texture (entropy at SSF = 6) and FDG uptake (TLG) was the only
best independent predictor of survival (HR = 44.7, 95% CI = 4.0–505.5, p = 0.002, Table 2).
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Table 2. Summary of multivariate Cox regression analysis model comprising of the most significant
univariate FWC texture, FDG uptake, and ADC parameters.
Parameter Included in the Model HR 95% CI p-Value
Entropy SSF = 6 * TLG 44.7 4.0–505.5 0.002
Parameters Not Included in the Model Score p-Value
Entropy SSF = 6 4.1 0.042
TLG 0.3 0.613
Skewness of ADC maps 0.03 0.867
TLG * Skewness of ADC maps 1.7 0.190
Entropy SSF = 6 * Skewness of ADC maps 0.03 0.867
* indicates the interaction between the covariates.
3.4. Gene Mutation Association with FWC Texture Parameters
Gene mutation status was available for 12 of 30 patients. Amongst the prognostic
imaging markers, FWC texture entropy at SSF = 6 had significantly higher number of
gene mutations per patient in the good prognostic (low entropy) group (medians 7 vs. 1.5,
p = 0.009). Specifically, KRAS S65 N and KRAS A59 T gene mutations were significantly
higher in the good prognostic (low entropy) group as identified by FWC texture entropy
at SSF = 6 (p = 0.002 and p = 0.015, respectively). Another gene mutation PIK3CA was
significantly (moderately) higher in the good prognostic (low entropy) group as identified
by FWC texture entropy at SSF = 2–5 (p = 0.045). Figure 5 shows a gene map representing
all gene mutation status available for the 12 patients divided into the good (low value of
the imaging marker) and poor (high value of the imaging marker) prognostic groups as
identified by FWC texture parameter (entropy at SSF = 6) and FDG uptake (SUVmean).
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4. Discussion
Authors should discuss the results and how they can be interpreted from the perspec-
tive of previous studies and of the working hypotheses. The findings and their implications
should be discussed in the broadest context possible. Future research directions may also
be highlighted.
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Extending the use of PET/MRI beyond simple diagnosis has been identified as a
means to add clinical value beyond PET/CT or MRI alone to enable this technology to
become a cost-effective imaging modality in clinical practice [1]. In this pilot study, we
demonstrate the potential for texture analysis of fractional water content images derived
from Dixon sequence (also used for AC) to meet this requirement. We show that tex-
ture analysis of fractional water content (FWC) images benefits from good inter-observer
agreement, generates biological relevant information related to TLG and gene mutation
count, and is associated with OS for patients with primary colorectal cancer. The use of
routinely acquired Dixon sequences (which could well be part of the AC images) facilitates
incorporation of the technique into clinical workflows.
The authors have been unable to identify previous research reporting tumor FWC
values derived using two-point Dixon sequences. Therefore, it is not possible to directly
compare our results for inter-observer agreement to previous research. We have calculated
tumor water content because of its greater relevance to tumor biology than fat content.
Nevertheless, our method for calculating FWC is analogous to determination of signal
fat fraction (FF) using two-point Dixon sequences, which is a parameter used clinically
(FWC = 1 − FF). The ICC values for inter-observer agreement from our study are compara-
ble to those reported for FF values derived from two Dixon images (i.e., 1 − water-fraction)
in muscle [40,41].
FWC texture parameters reflect the distribution of water within the tumor tissue. The
correlation we found between FWC texture and TLG points to the biological significance
of tumor water distribution, as TLG reflects a combination of two important tumor char-
acteristics, overall size and glycolytic activity. Coarse texture entropy was also an FWC
texture parameter that correlated significantly with TLG in our study (rs = 0.498, p = 0.005,
Table S3).
Seven of the ten strongest FWC texture correlates for TLG comprised negative asso-
ciations with either mean intensity values or the mean of positive pixels. These texture
parameters increase in value depending on the number and intensity of bright objects
highlighted by the filtration step [8]. This finding suggests that tumors containing more
focal areas with high water content tend to be smaller and/or less glycolytic. Several
possible explanations can be proposed for an inverse relationship with glycolysis. Areas
with higher fractional water content could represent areas with greater cellular density but
with a high proportion of non-glycolytic cells. Alternatively, a high local water content
could reflect more extracellular fluid or regions of necrosis. Further work will be required
to determine the biological correlates for FWC texture parameters.
Five FWC texture parameters were significantly associated with OS, of which four
were also identified as correlates for TLG. We also found TLG to be the metabolic parameter
most significantly associated with survival, consistent with a previous study of colorectal
cancer patients prior to treatment [42]. Our threshold value for TLG in determining
prognostic groups (≥378 indicating poor prognosis), and the proportion of patients above
the threshold (10%) were also similar to that study (342 and 13%, respectively). In both
cases, the mismatch in the sizes of the prognostic groups is a constraint on the usefulness of
TLG as a prognostic marker. In comparison, the sizes of good and poor prognostic groups
were much more even for FWC texture parameters, while the statistical significance for the
association between FWC texture expressed as coarse entropy and OS was close to that
found for TLG. FWC texture also benefited from identifying a good prognosis group with
zero mortality.
Genetic analysis demonstrated a high tumor gene mutation count in patients with
good prognosis as measured by low FWC texture entropy. Previous reports have hypothe-
sized that a higher number of gene mutations results in a greater number of tumor specific
neo-antigens [43]. This, in turn, stimulates an infiltration of T-lymphocytes and thus an
up-regulation of immune checkpoints. An alternative hypothesis for good prognosis is that
cell viability decreases as genomic instability increases, as reflected by a greater number
of gene mutations [44]. Significant mutations seen in the genetic analysis included KRAS
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A59T and S65N. KRAS is a well-documented activating driver mutation associated with
CRC. Missense mutations in codons 12 and 13 on exon 2 are reported in over 75% of CRC
cases and linked with no response to anti-EGFR therapy [45]. KRAS S65N mutation is
not reported in the literature and appears to be a novel mutation associated with CRC.
Interestingly, case studies have found KRAS A59T positive CRC respond to anti-EGFR
therapy, which is contrary to current treatment guidelines for KRAS positive tumors [45].
Texture analysis using the filtration-histogram approach has also been applied to CT
images of primary tumors, including the low-dose CT used for attenuation correction in
PET/CT [16]. Correlations between CT texture and tumor metabolic parameters have
been demonstrated for non-small lung cancer (NSCLC) and esophageal cancer [46,47], and
between CT texture and OS in colorectal cancer [15]. In all of these examples, CT texture
quantified as entropy was among the significant parameters, corresponding to the promi-
nence of entropy values in our study. Although the limitations of entropy as a surrogate
for tumor heterogeneity have been highlighted [48], this parameter may represent a means
of quantifying tumor heterogeneity regardless of imaging technique. Nevertheless, the
application of texture analysis to the routinely acquired Dixon sequences (which could well
be used for AC increasing the utility of existing images) part of PET/MRI has advantages
over a comparable use in PET/CT, including reduced radiation exposure and the ability to
combine texture analysis with a wider range of other quantitative imaging techniques. The
importance of filtration-histogram approach to texture analysis is further highlighted by the
fact that no unfiltered texture parameters (including the fractional water content measure,
although generally higher in colorectal tumors) showed any significant association with
functional imaging parameters, patient prognosis and gene mutation profile.
A further notable finding in our study is that histogram analysis of tumor ADC
values can also potentially provide prognostic information for patients with colorectal
cancer. The capacity for kurtosis and/or skewness values of ADC histograms to distinguish
benign and malignant lesions, and to predict or assess treatment response has been shown
for a range of tumor types [49]. In rectal cancer, the skewness of the ADC histogram
was found to be related to tumor stage and the presence of extramural invasion [50].
However, inclusion of DWI within PET/MRI protocols creates economic challenges for
this modality. The time required for DWI is much longer than that needed for Dixon
sequences, extending the image acquisition time beyond that required for acquisition of
PET data. In these circumstances, the PET/MRI system is effectively being used for MRI
alone for significant periods. This mode of utilization is economically undesirable given
the high cost of these devices. In addition, standard whole-body DWI acquisitions used in
PET/MRI are subject to distortion artefacts, which can lead to mis-registration between
PET and MRI datasets. A recent PET/MRI study of 20 oncological patients reported
19 distortion artefacts when using standard DWI sequences [51]. The frequency of artefacts
increased when a simultaneous multi-slice technique was used to reduce acquisition time.
Anatomical distortion during DWI can be reduced by the use of multi-shot echo planar
imaging, but these techniques require even longer image acquisitions, further increasing the
economic challenges. Furthermore, biomarkers derived from Dixon sequences part of MR-
only acquisition have been shown to benefit from superior reproducibility as compared
to ADC values [52], providing insights in pathophysiology [53] and early response to
treatment [54]. In addition to the benefits of superior reproducibility of Dixon sequences,
the use of filtration-histogram-based texture analysis has demonstrated less variance
(increased robustness) to image acquisition parameter changes [55,56].
This study is limited by the relatively small number of patients, commensurate with
an initial, pilot feasibility study, whereby we could not apply a power analysis to determine
an appropriate size of the study population. However, we undertook an inter-operator
agreement between the two readers for the FWC texture quantification and only the
parameters that showed good or excellent ICC were included for subsequent analysis. To
address the multiple comparison issue arising in the process of identifying a functional
imaging correlate for FWC texture parameters, the Benjamini–Hochberg correlation was
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applied to reduce the false discovery rate. It is worth noting that the tumor ROI contour
was drawn on a single axial slice. Although the multi-slice or volume delineation would
be a better representation of the whole tumor, such a methodology is time-consuming and
therefore not practical in a clinical setting. Furthermore, comparable results in texture-
based heterogeneity assessment have been reported between cross-sectional area and whole
volume analysis in colorectal cancer on CT [57] and gliomas on MRI [27]. Finally, the use of
optimized threshold values for survival analysis may have over-estimated the prognostic
ability, not only for FWC texture but also tumor metabolic and ADC parameters. The
potential prognostic value of FWC texture needs to be confirmed in larger studies with
separate cohorts for derivation of threshold and validation of prognostic performance. Our
study methodology, although keeping in mind the feasibility nature, has been described in
detail above, which more or less adheres to the REMARK guidelines/checklist aimed at
improving the reporting of these types of outcome studies [58]. It will be recommended to
follow the REMARK guidelines/checklist in future studies validating our feasibility results
in a larger prospective population.
Two general applications beyond simple diagnosis that have been identified as having
the potential to render PET/MRI cost-effective in clinical practice are risk-adapted post-
operative surveillance and selection of patients for targeted therapy [1]. Both scenarios are
highly relevant to patients with colorectal cancer. Most patients with operable colorectal
cancer undergo post-operative surveillance with a view to early detection of treatable
tumor recurrence. The efficacy of surveillance can be increased, and costs reduced by
de-escalating follow-up in patients with a good prognosis [59]. There has also been recent
interest in the use of immune checkpoint inhibitor therapy for colorectal cancer in the
neoadjuvant setting [60]. PET/MRI markers could potentially identify those patients
most likely to benefit from these agents and/or those who may need additional adjuvant
chemotherapy. The association we found between prognostic group as determined by
FWC texture and gene mutation count is particularly germane in this context, given the
recognized importance of tumor mutation burden in determining response to immune
checkpoint inhibitors. Although further research specific to these scenarios is required,
the prognostic ability shown in our study suggests that FWC texture analysis may able to
unlock these clinical applications for PET/MRI.
5. Conclusions
The use of imaging-based texture analysis as a marker of tumor heterogeneity for
determining tumor prognosis, characterization and assessing response to therapy is gaining
momentum as a clinical tool [10]. Texture analysis of FWC images derived from routine
PET/MRI Dixon acquisitions (also part of the AC images) shows good inter-operator agree-
ment, generates biological relevant information related to TLG and gene mutation count,
and provides prognostic information that can potentially unlock new clinical applications
for patients with colorectal cancer.
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